Top Story

Neurocrine Biosciences launches trial for congenital adrenal hyperplasia therapy

December 21, 2014

After completing a pilot clinical trial in adults with classic congenital adrenal hyperplasia, Neurocrine Biosciences, Inc. announced a trial for its proprietary corticotropin releasing factor 1 receptor antagonist in adolescents, according to a statement from the company.

The open-label, sequential cohort, single-ascending dose trial, known as the 1401 Study, for the drug NBI-77860 will involve approximately 15 adolescent girls with classic congenital adrenal hyperplasia (CAH), according to the statement.

New next-generation sequencing test launched for thyroid nodules

December 20, 2014
Interpace Diagnostics, a molecular diagnostics subsidiary of PDI, Inc., has recently launched a new next-generation sequencing test designed to determine the difference…
In the Journals

Lower risk for type 2 diabetes among people with type O blood

December 19, 2014
People with the blood types A, B and AB have a higher risk for developing type 2 diabetes than those with type O, according to recent study findings published in…
In the Journals

Nonenhanced neck CT may detect diffuse thyroid disease

December 19, 2014
Nonenhanced CT images are effective for differentiating diffuse thyroid disease from normal thyroid, according to recent findings published in the International Journal

CMS releases new quality of care data on physicians, ACOs, hospitals

December 19, 2014
CMS released new data on the quality of care provided by physician group practices, hospitals and Accountable Care Organizations, according to the CMS Blog.Included in…
More News Headlines »
low no

Low- and No-Calorie Sweeteners in Weight Management: What Do You Need to Know?

This activity is supported by an educational grant from the American Beverage Association.

The use of low- and no-calorie sweeteners continues to grow as consumers continue to purchase foods and beverages…
More »
Meeting News Coverage Video
thumbnail for video 3890508474001

Lenvatinib, sorafenib may significantly impact treatment of differentiated thyroid cancer

November 13, 2014
Marcia S. Brose, MD, PhD, associate professor at the University of Pennsylvania and director of the thyroid cancer…
More »
Experts Take: Dialogue on HTG

Experts’ Take: Dialogue on Hypertriglyceridemia

This activity is supported by an independent educational grant from Amarin Pharma Inc.

Lead by genetic studies, recent data describe a causal role of triglycerides (TG) in the formation of atherosclerosis…
More »